Welcome to our dedicated page for BioNxt Solutions news (Ticker: BNXTF), a resource for investors and traders seeking the latest updates and insights on BioNxt Solutions stock.
BioNxt Solutions Inc. (BNXTF) is a bioscience innovator developing advanced drug delivery platforms for autoimmune and neurological conditions. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on BioNxt’s sublingual thin-film technologies, transdermal delivery systems, and regulatory progress across global markets. Key updates include partnership agreements with European CRDMOs, intellectual property filings, and clinical pipeline advancements targeting conditions like multiple sclerosis and lupus nephritis.
All content undergoes strict verification to ensure accuracy and relevance. Regular updates cover:
• Strategic collaborations with pharmaceutical partners
• Regulatory submissions and quality compliance achievements
• Product development milestones in drug delivery innovation
• Intellectual property portfolio expansions
Bookmark this page for direct access to BioNxt’s official communications and analyzed market developments. For comprehensive investment research, combine these updates with SEC filings and financial disclosures.
BioNxt Solutions (OTC:BNXTF) has announced a non-brokered private placement of convertible debenture units priced at $0.60 per unit, aiming to raise up to $1.2 million in gross proceeds.
Each debenture unit includes an 8.0% unsecured convertible debenture and one common share purchase warrant. The warrants allow holders to acquire common shares at $0.75 per share within two years. The debentures are convertible into common shares at $0.60 per share before maturity.
The company plans to use proceeds for product development, commercialization, intellectual property filings, and working capital. The offering may include finder's fees of up to 8% cash and 8% in broker warrants.
BioNxt Solutions (OTC:BNXTF) has unveiled a groundbreaking targeted chemotherapy delivery platform designed to enhance precision oncology treatment. The proprietary targeted drug delivery system (TDDS) employs a dual-action mechanism that concentrates chemotherapy near tumors while neutralizing drug molecules outside tumor sites.
The platform has demonstrated potential for a 10-fold increase in therapeutic effect while protecting healthy cells. Compatible with over 100 established chemotherapy agents, the technology targets a chemotherapy-drug market projected to reach USD 98 billion by 2030. BioNxt will acquire an 80% interest in the technology through development funding and milestone-based share issuance over 36 months.
BioNxt Solutions (OTC:BNXTF) has reached a significant milestone in its multiple sclerosis (MS) drug development program with the receipt of the active pharmaceutical ingredient (API) for BNT23001, their proprietary sublingual thin-film formulation of cladribine.
The company will now proceed with clinical batch manufacturing through their European partner, Gen-Plus GmbH & Co KG, in preparation for a human bioequivalence study planned for H2 2025. BNT23001 is designed as an alternative to traditional oral cladribine tablets like Mavenclad®, offering a rapidly dissolving sublingual film particularly beneficial for MS patients with swallowing difficulties.
Preclinical studies have shown promising results with high absorption rates and bioequivalence to existing oral therapies, without toxic effects. The company is also advancing patent applications in key markets including Europe, the US, and Canada.
BioNxt Solutions (OTC:BNXTF) announced that the British Columbia Securities Commission has revoked the temporary management cease trade order (MCTO) that was previously issued on May 1, 2025. The revocation comes after the company successfully filed its required annual financial documents for the year ended December 31, 2024.
The completion of these filings means that company management can now resume trading BioNxt securities. All annual filings are now accessible through the company's SEDAR+ profile.
BioNxt Solutions (BNXTF) has received formal notice from the European Patent Office (EPO) of their intention to grant the company's core patent for sublingual delivery of anticancer drugs treating autoimmune neurodegenerative diseases. The patent is particularly significant for BNT23001, their lead product - a sublingual thin-film formulation of Cladribine designed to treat multiple sclerosis (MS).
The company is advancing patent protection through the EPO, Eurasian Patent Organization, and independent nations including Australia, Canada, New Zealand, USA, and Japan. This intellectual property will support BioNxt's pipeline of sublingual products targeting various autoimmune diseases including MS, myasthenia gravis, lupus nephritis, and rheumatoid arthritis.
BioNxt Solutions (BNXTF) has announced the consolidation of its research, development, and commercialization activities at the Gen-Plus CRDO facility in Munich, Germany. The integration provides access to a 1,000-square-meter state-of-the-art laboratory space equipped for high-potency pharmaceutical development and GMP-compliant processes.
The company will leverage Gen-Plus's advanced infrastructure to enhance its drug delivery systems, focusing on their lead product BNT23001, a sublingual thin-film formulation of Cladribine for multiple sclerosis treatment. Immediate plans include preparation for human bioequivalence studies, including placebo trials, product transfer, manufacturing upscaling, and analytical validation.
FAQ
What is the current stock price of BioNxt Solutions (BNXTF)?
What is the market cap of BioNxt Solutions (BNXTF)?
